Billionaire Paul Allen's foundation is funding a new type of evacuation "cocoon" to help fly sick medical workers from West Africa
If you can't beat them, avoid them.
The Pentagon commits to planning for higher temperatures, and retired generals line up to help
Mobile food startups are moving beyond delivery into food prep
Cities relax or abandon purchasing restrictions in a bid to avoid more serious downturn
Ministry of Supply’s Aviator jacket combines the structure of a tailored garment with the functionality of a windbreaker
The Department of Education may double the number of debt collectors who go after defaulted federal student loans
This year's must-have Silicon Valley office accessory: a $199 bear costume
By Pete Engardio
For nearly two decades, America's life sciences industry has benefited from a Chinese brain drain. Since 1985 some 10,000 mainlanders have earned biomedicine PhDs in the U.S.—and the vast majority stayed to work at U.S. pharmaceutical companies and research universities. Now some of China's brightest brains are returning home to start drug-research companies, run university programs, and establish operations for multinationals.
China's gain is not necessarily America's loss, however. Most of these "sea turtles," as the returnees are known, are building strategic tieups with U.S. drugmakers that could expand their pipelines of new drugs, speed up development time, reduce R&D costs—and gain inroads to China's rapidly growing drug market. Others are founding U.S. companies with China operations.
Following are some of the most influential sea turtles.